Works matching IS 17762596 AND DT 2025 AND VI 20 AND IP 1
Results: 15
Fruquintinib Plus Sintilimab in Patients with Treatment-Naive and Previously Treated Advanced Renal Cell Carcinoma: Results from a Phase Ib/II Clinical Trial: Fruquintinib Plus Sintilimab in Patients with Advanced Renal Cell Carcinoma: H. Xu et al.
- Published in:
- Targeted Oncology, 2025, v. 20, n. 1, p. 113, doi. 10.1007/s11523-024-01120-6
- By:
- Publication type:
- Article
FGFR-Altered Urothelial Carcinoma: Resistance Mechanisms and Therapeutic Strategies: FGFR-Altered Urothelial Carcinoma: D. J. Benjamin, A. C. Mita.
- Published in:
- Targeted Oncology, 2025, v. 20, n. 1, p. 1, doi. 10.1007/s11523-024-01119-z
- By:
- Publication type:
- Article
Efficacy and Safety of Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Real-World Studies: CDK4/6 Inhibitors for Patients with Breast Cancer: H.-C. Su et al.
- Published in:
- Targeted Oncology, 2025, v. 20, n. 1, p. 71, doi. 10.1007/s11523-024-01118-0
- By:
- Publication type:
- Article
Defining the Position of [<sup>177</sup>Lu]Lu-PSMA Radioligand Therapy in the Treatment Landscape of Metastatic Castration-Resistant Prostate Cancer: A Meta-analysis of Clinical Trials: [<sup>177</sup>Lu]Lu-PSMA RLT in mCRPC: A Meta-analysis of Clinical Trials: C. Ciccarese et al
- Published in:
- Targeted Oncology, 2025, v. 20, n. 1, p. 103, doi. 10.1007/s11523-024-01117-1
- By:
- Publication type:
- Article
Immunotherapy Following Anaplastic Lymphoma Kinase Inhibitor Therapy for Patients with Anaplastic Lymphoma Kinase‑Positive Non‑small Cell Lung Cancer in Japan: Immunotherapy Following ALK Inhibitors for Patients with ALK-Positive NSCLC in Japan: Y. Shimomura et al
- Published in:
- Targeted Oncology, 2025, v. 20, n. 1, p. 171, doi. 10.1007/s11523-024-01116-2
- By:
- Publication type:
- Article
IDH1/2 Mutations in Cancer: Unifying Insights and Unlocking Therapeutic Potential for Chondrosarcoma: IDH1/2 Mutations in Chondrosarcoma: S. Deshmukh et al.
- Published in:
- Targeted Oncology, 2025, v. 20, n. 1, p. 13, doi. 10.1007/s11523-024-01115-3
- By:
- Publication type:
- Article
Adjuvant Immune Checkpoint Inhibitors for Muscle-Invasive Urothelial Carcinoma: An Updated Systematic Review, Meta-analysis, and Network Meta-analysis: Adjuvant Immunotherapy for Urothelial Carcinoma: T. Yanagisawa et al.
- Published in:
- Targeted Oncology, 2025, v. 20, n. 1, p. 57, doi. 10.1007/s11523-024-01114-4
- By:
- Publication type:
- Article
Post-Metastasis Survival of Patients with High-Risk Localized and Locally Advanced Prostate Cancer Undergoing Primary Treatment in the United States: A Retrospective Study: Post-Metastasis Survival of Patients with High-Risk Localized and Locally Advanced Prostate Cancer: Stephen J. Freedland et al
- Published in:
- Targeted Oncology, 2025, v. 20, n. 1, p. 139, doi. 10.1007/s11523-024-01113-5
- By:
- Publication type:
- Article
Durvalumab Following Chemoradiotherapy for Stage III Non-small Cell Lung Cancer: Differences in Survival Based on Age and Post-Progression Systemic Therapy: PACIFIC Regimen: Survival Based on Age and Subsequent Therapy: D. Ksienski et al.
- Published in:
- Targeted Oncology, 2025, v. 20, n. 1, p. 149, doi. 10.1007/s11523-024-01111-7
- By:
- Publication type:
- Article
Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors: Adavosertib Plus Durvalumab for Solid Tumors: A Phase I Study: M.R. Patel et al.
- Published in:
- Targeted Oncology, 2025, v. 20, n. 1, p. 127, doi. 10.1007/s11523-024-01110-8
- By:
- Publication type:
- Article
Unveiling the Digital Evolution of Molecular Tumor Boards: Unveiling the Digital Evolution of Molecular Tumor Boards: S. Lutz et al.
- Published in:
- Targeted Oncology, 2025, v. 20, n. 1, p. 27, doi. 10.1007/s11523-024-01109-1
- By:
- Publication type:
- Article
Delayed Separation of Kaplan–Meier Curves is Commonly Observed in Studies of Advanced/Metastatic Solid Tumors Treated with Anti-PD-(L)1 Therapy: Systematic Review and Meta-Analysis: Delayed Separation of KM Curves with Anti-PD-(L)1 Therapy: D.-Y. Oh et al
- Published in:
- Targeted Oncology, 2025, v. 20, n. 1, p. 45, doi. 10.1007/s11523-024-01108-2
- By:
- Publication type:
- Article
Risk and Benefit for Basket Trials in Oncology: A Systematic Review and Meta-Analysis: Risk and Benefit for Basket Trials in Oncology: K. Klas et al.
- Published in:
- Targeted Oncology, 2025, v. 20, n. 1, p. 89, doi. 10.1007/s11523-024-01107-3
- By:
- Publication type:
- Article
Correction: Ivosidenib: A Review in Advanced Cholangiocarcinoma: Correction: Ivosidenib: A Review in Advanced Cholangiocarcinoma: J. E. Frampton et al.
- Published in:
- 2025
- By:
- Publication type:
- Correction Notice
Optimal Duration of Consolidation Durvalumab Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer: A Multi-institutional Retrospective Study: Duration of Durvalumab Following CCRT in Stage III NSCLC: H. Doi et al.
- Published in:
- Targeted Oncology, 2025, v. 20, n. 1, p. 161, doi. 10.1007/s11523-024-01105-5
- By:
- Publication type:
- Article